MAP Pharmaceuticals Initiates Phase 3 Clinical Trial In Patients With Migraine
MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced it has initiated its Phase 3 clinical program to evaluate MAP0004 as a potential treatment for migraine.
Archive for Headache / Migraine
Combination Drug Taken Early Relieves Migraine Symptoms
A combination drug taken within an hour after the start of a migraine is effective in relieving symptoms, according to research published in the July 8, 2008, issue of Neurology®, the medical journal of the American Academy of Neurology.